Oral chemotherapy as second-line treatment option for gemcitabine-refractory advanced pancreatic cancer with poor performance status.

被引：0
|
作者：
Park, Se Jun
Lee, Myung Ah
机构：
[1] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[2] Catholic Univ Korea, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.405
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
405
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A systemic review and meta-analysis to evaluate the efficacy and postprogression survival of second-line chemotherapy for gemcitabine-refractory pancreatic cancer.
    Kasuga, Akiyoshi
    Hamamoto, Yasuo
    Aoki, Yu
    Kawasaki, Kenta
    Suzuki, Takeshi
    Hirata, Kenro
    Sukawa, Yasutaka
    Takaishi, Hiromasa
    Kanai, Takanori
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer
    Boeck, Stefan
    Heinemann, Volker
    FUTURE ONCOLOGY, 2008, 4 (01) : 41 - 50
  • [23] Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
    Girardi, Daniel M.
    Faria, Luiza Dib B. B.
    Teixeira, Marcela C.
    Costa, Frederico P.
    Hoff, Paulo Marcelo G.
    Fernandes, Gustavo S.
    JOURNAL OF GASTROINTESTINAL CANCER, 2019, 50 (04) : 860 - 866
  • [24] Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
    Daniel M. Girardi
    Luiza Dib B. B. Faria
    Marcela C. Teixeira
    Frederico P. Costa
    Paulo Marcelo G. Hoff
    Gustavo S. Fernandes
    Journal of Gastrointestinal Cancer, 2019, 50 : 860 - 866
  • [25] Paclitaxel as a Salvage Chemotherapy in Patients With Gemcitabine-Refractory Pancreatic Cancer
    Maeda, S.
    Motoi, F.
    Kawaguchi, K.
    Onogawa, T.
    Morikawa, T.
    Okaue, A.
    Takadate, T.
    Rikiyama, T.
    Katayose, Y.
    Egawa, S.
    Unno, M.
    PANCREAS, 2009, 38 (08) : 1024 - 1024
  • [26] An Analysis of a Second-Line S-1 Monotherapy for Gemcitabine-Refractory Biliary Tract Cancer
    Katayose, Yu
    Ohtsuka, Hideo
    Kitamura, Yo
    Masuda, Kunihiro
    Nakagawa, Kei
    Yamamoto, Kuniharu
    Yoshida, Hiroshi
    Onogawa, Tohru
    Motoi, Fuyuhiko
    Naitoh, Takeshi
    Rikiyama, Toshiki
    Egawa, Shin-ichi
    Unno, Michiaki
    HEPATO-GASTROENTEROLOGY, 2012, 59 (115) : 691 - 695
  • [27] SECOND-LINE CHEMOTHERAPY IN GEMCITABINE PRETREATED ADVANCED PANCREATIC CANCER: ANALYSES ON PROGNOSTIC AND PREDICTIVE FACTORS
    Cha, Y.
    Oh, D.
    Lee, S.
    Kim, D.
    Im, S.
    Kim, T.
    Heo, D. S.
    Bang, Y.
    ANNALS OF ONCOLOGY, 2008, 19 : 181 - 181
  • [28] Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Kulke, Matthew H.
    Blaszkowsky, Lawrence S.
    Ryan, David P.
    Clark, Jeffrey W.
    Meyerhardt, Jeffrey A.
    Zhu, Andrew X.
    Enzinger, Peter C.
    Kwak, Eunice L.
    Muzikansky, Alona
    Lawrence, Colleen
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4787 - 4792
  • [29] Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer
    Kawashima, Hiroki
    Itoh, Akihiro
    Ohno, Eizaburo
    Nakamura, Masanao
    Miyahara, Ryoji
    Ohmiya, Naoki
    Hara, Kazuo
    Kanamori, Akira
    Itoh, Terutomo
    Taki, Tomoyuki
    Hirai, Takanori
    Hashimoto, Senju
    Takeda, Kinichi
    Goto, Hidemi
    Hirooka, Yoshiki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (03) : 677 - 683
  • [30] Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer
    Hiroki Kawashima
    Akihiro Itoh
    Eizaburo Ohno
    Masanao Nakamura
    Ryoji Miyahara
    Naoki Ohmiya
    Kazuo Hara
    Akira Kanamori
    Terutomo Itoh
    Tomoyuki Taki
    Takanori Hirai
    Senju Hashimoto
    Kinichi Takeda
    Hidemi Goto
    Yoshiki Hirooka
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 677 - 683
12345